证券代码：603718 证券简称：海利生物 公告编号：2026-007 上海海利生物技术股份有限公司 董事兼总经理增持公司股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 增持主体的基本情况 截至本公告披露日，上海海利生物技术股份有限公司（以下简称"公司"） 董事兼总经理韩本毅先生持有公司股份 1,980,000 股，占公司总股本的 0.30%。 增持计划的主要内容 基于对公司发展前景的信心和公司股票长期投资价值的认可，为维护股东利 益，增强投资者信心，公司董事兼总经理韩本毅先生计划自愿以自有或自筹资金 在本公告日起 6 个月内通过上海证券交易所交易系统以集中竞价的方式增持公 司股份，预计累计增持金额不低于人民币 150 万元，不超过人民币 200 万元。 本次增持计划不设价格区间。 增持计划无法实施风险 本次增持计划的实施可能存在因资本市场发生变化等因素，导致本次增持计 划无法达到预期的风险。如本次增持计划实施过程中出现上述风险情况，公司将 及时履行信息披露义务。 公司于 2026 年 ...

证券代码：603718 证券简称：海利生物 公告编号：2026－005 上海海利生物技术股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1、经财务部门初步测算，预计公司 2025 年度实现利润总额 3,400 万元到 4,000 万元，实现归属于母公司所有者的净利润 1,100 万元到 1,600 万元，归属 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况 （一）利润总额：208,117,455.78 元。归属于母公司股东的净利润： 171,180,295.61 元。归属于母公司股东的扣除非经常性损益的净利润： 10,581,377.63 元。 （二）每股收益：0.26 元。（以最新股本 651,904,700 股计算） （三）营业收入：271,039,818.26 元。 三、本期业绩下滑的主要原因 1、2024 年公司因出 ...

Core Viewpoint - The animal health sector experienced a slight decline of 0.23% on January 30, with Jinhe Biological leading the drop. The Shanghai Composite Index closed at 4117.95, down 0.96%, while the Shenzhen Component Index closed at 14205.89, down 0.66% [1]. Group 1: Stock Performance - The closing prices and performance of key stocks in the animal health sector showed varied results, with Huisheng Biological rising by 3.51% to 29.46, while Jinhe Biological fell by 2.98% to 6.51 [1][2]. - The trading volume for Huisheng Biological was 303,100 shares, with a transaction value of 901 million yuan, indicating strong market interest [1]. Group 2: Capital Flow - The animal health sector saw a net inflow of 59.82 million yuan from institutional investors, while retail investors experienced a net outflow of 81.83 million yuan, indicating a shift in investor sentiment [2][3]. - Among individual stocks, Huisheng Biological attracted a significant net inflow of 1.23 billion yuan from institutional investors, while Jinhe Biological faced a net outflow of 543.32 million yuan [3].

Core Viewpoint - The animal health sector experienced a slight decline of 0.2% on January 28, with Yongshun Biological leading the drop, while the overall market indices showed minor gains [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4151.24, up by 0.27% [1]. - The Shenzhen Component Index closed at 14342.9, up by 0.09% [1]. - The animal health sector's performance is summarized in a table showing individual stock movements, with notable gainers including Biological Shares and Jinhai Biological, which rose by 1.51% and 1.49% respectively [1]. Group 2: Stock Performance - Yongshun Biological saw a significant decline of 7.49%, closing at 10.13, with a trading volume of 141,500 shares and a turnover of 145 million yuan [2]. - Other notable decliners included Shoufeng Holdings and Haili Biological, which fell by 2.21% and 2.08% respectively [2]. - The trading volume and turnover for various stocks in the animal health sector are detailed, indicating varied investor interest [2]. Group 3: Capital Flow - The animal health sector experienced a net inflow of 18.02 million yuan from institutional investors, while retail investors saw a net inflow of 9.33 million yuan [2]. - However, there was a net outflow of 27.35 million yuan from speculative funds, indicating a mixed sentiment among different investor types [2]. - A detailed table shows the net capital flow for individual stocks, highlighting significant movements in and out of various companies [3].

Market Overview - The animal health sector experienced a decline of 2.78% on January 27, with Huisheng Biological leading the drop [1] - The Shanghai Composite Index closed at 4139.9, up 0.18%, while the Shenzhen Component Index closed at 14329.91, up 0.09% [1] Stock Performance - Key stocks in the animal health sector showed varied performance, with the following notable changes: - Huisheng Biological (300871) closed at 29.89, down 8.37% with a trading volume of 376,900 shares and a transaction value of 1.148 billion [2] - Other significant declines included: - ST Lvkang (002868) down 3.86% to 35.40 [1] - Kexin Biological (688526) down 3.88% to 17.10 [1] - Haili Biological (603718) down 4.13% to 6.73 [1] Capital Flow - The animal health sector saw a net outflow of 45.7033 million from institutional investors, while retail investors experienced a net outflow of 59.3359 million [2] - Conversely, speculative funds recorded a net inflow of 105 million [2] Individual Stock Capital Flow - Notable capital flow for specific stocks included: - ST Lvkang (002868) had a net inflow of 29.8876 million from institutional investors, but a net outflow of 40.6641 million from speculative funds [3] - Zhongmu Co. (600195) saw a net inflow of 21.2767 million from institutional investors, with a significant net outflow of 66.5383 million from retail investors [3] - Jinhe Biological (002688) had a net inflow of 19.2937 million from institutional investors, but also faced a net outflow from retail investors [3]

Group 1 - The animal health sector experienced a significant increase of 5.61% on January 26, with Yongshun Biological leading the gains [1] - The Shanghai Composite Index closed at 4132.61, down 0.09%, while the Shenzhen Component Index closed at 14316.64, down 0.85% [1] - Key stocks in the animal health sector showed notable price increases, with Yongshun Biological rising by 27.18% to a closing price of 11.79, and Huisheng Biological increasing by 20.01% to 32.62 [1] Group 2 - The animal health sector saw a net inflow of 437 million yuan from institutional investors, while retail investors experienced a net outflow of 307 million yuan [2] - The trading volume for Yongshun Biological reached 292,600 shares, contributing to a total transaction value of 328 million yuan [1][2] - The stock performance of various companies in the sector varied, with some experiencing significant gains while others faced declines in retail investment [3]

Core Viewpoint - The agricultural, animal husbandry, and fishery sector is experiencing a strong upward trend, with the only agricultural ETF (159275) showing a price increase of 1.53%, recovering key moving averages [1][9][10] Group 1: Market Performance - The agricultural ETF (159275) opened with fluctuations but quickly surged, recovering the 5-day, 10-day, and 20-day moving averages [1][9] - Key stocks in the sector, such as Huisheng Biological and Lain Biological, reached their daily limit, while others like Haili Biological and Jinhai Biological saw significant gains [10][12] Group 2: Industry Insights - The pig farming sector faces supply pressures, and policy guidance may accelerate capacity reduction [12][13] - The poultry farming sector is influenced by frequent outbreaks of avian influenza, creating uncertainty in breeding stock imports, which could benefit the white feather chicken industry in the medium to long term [12][13] - The animal health industry continues to show potential for growth, with new products being launched to drive revenue [12][13] Group 3: Valuation and Investment Opportunities - The current valuation of the agricultural sector is relatively low, with the agricultural ETF's underlying index showing a price-to-book ratio of 2.5, placing it at the 23.53 percentile over the past five years, indicating a favorable long-term investment opportunity [3][12] - Investors are encouraged to consider the agricultural ETF (159275) for exposure to leading companies in the pig farming sector and other segments of the agricultural value chain [13][12]

Group 1 - The company, Shanghai Haili Biological Technology Co., Ltd., announced that its wholly-owned subsidiary, Shanghai Jiemen Biotechnology Co., Ltd., has received a renewed Medical Device Manufacturing License from the Shanghai Municipal Drug Administration [2] - The renewal extends the license validity until January 3, 2031, and changes the production address to "Room 102, 202, 502, No. 66, Hengyu Road, Jiading District, Shanghai" [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海海利生物技术股份有限公司（以下简称"公司"）全资子公司上海捷门生物 技术有限公司（以下简称"捷门生物"）于近日收到上海市药品监督管理局换发的《医 疗器械生产许可证》，本次变更系许可证有效期延长至 2031 年 1 月 3 日及生产地 址变更为"上海市嘉定区恒裕路 66 弄 1 号 102 室、202 室、502 室"。变更后的具体 情况如下： 证券代码：603718 证券简称：海利生物 公告编号：2026－004 上海海利生物技术股份有限公司 关于全资子公司医疗器械生产许可证变更的公告 生产范围：【原《分类目录》分类编码区】：Ⅱ类 6840 医用体外诊断试剂 # 【新《分类目录》分类编码区】：# 发证部门：上海市药品监督管理局 许可期限：自 2026 年 1 月 4 日至 2031 年 1 月 3 日 一、《医疗器械生产许可证》基本情况 许可证编号：沪药监械生产许 20041062 号 统一社会信用代码：91310105132752810W 企业名称：上海捷门生物技术有 ...

Core Viewpoint - The company, Haili Biological, announced that its wholly-owned subsidiary, Shanghai Jiemen Biotechnology Co., Ltd., has received a renewed Medical Device Manufacturing License from the Shanghai Municipal Drug Administration, extending the license validity until January 3, 2031, and changing the production address [1] Group 1 - The Medical Device Manufacturing License has been renewed, indicating regulatory compliance and operational continuity for the company [1] - The new production address is located at "Room 102, 202, 502, No. 66 Hengyu Road, Jiading District, Shanghai," which may reflect an expansion or relocation strategy [1] - The extension of the license validity to 2031 suggests a long-term operational outlook for the subsidiary [1]